title: [Intraperitoneal and intrapleural gemcitabine in patients with advanced pancreatic cancer].
abstract: We performed intraperitoneal and intrapleural dosing gemcitabine (GEM) to eight patients with advanced pancreatic cancer having peritoneal or pleural carcinomatosis and evaluated its actions and safety. GEM (500 mg/m2) was infused into the abdominal cavity or thoracic cavity after drainage of peritoneal or pleural effusion. We checked the change of serum GEM concentration and the side effects after the GEM administration. Then, we repeated the GEM administration observing their systematic symptoms and evaluated the alteration of peritoneal or pleural effusion and cytology. Plasma concentration of GEM by infusing into the abdominal cavity or thoracic cavity was lower than by intravenous injection. In three of the five cases of peritoneal carcinomatosis, intraperitoneal administration revealed a decrease of peritoneal effusion. In two of the three cases of pleural carcinomatosis, intrapleural administration revealed a decrease of pleural effusion. Four cases had leukocytopenia of grade 1/2, three cases had thrombocytopenia, and two cases had alopecia as side effects, although all of them were minor side effects. Intraperitoneal and intrapleural dosing GEM had minor side effects and could improve QOL for the patients with advanced pancreatic cancer associated with peritoneal or pleural carcinomatosis.
authors.affiliation: Gastroenterology Center, Tokeidai Hospital.
authors.forename: Takehide
authors.initials: T
authors.lastname: Akiyama
authors.forename: Hisato
authors.initials: H
authors.lastname: Homma
authors.forename: Shinichi
authors.initials: S
authors.lastname: Mezawa
authors.forename: Sho
authors.initials: S
authors.lastname: Takahashi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Koike
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Kogawa
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Hirata
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D035422:Pleural Cavity; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000556:secondary; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine